Frontier Pharma: Asthma- Identifying and Commercializing First- in- Class Innovation Published on – 01 May, 2015 | Number of pages : 67 Single User Price: $6995 “While the current asthma market is almost exclusively dominated by small molecules, which account for approximately 99% (the exception being Xolair), the current asthma pipeline includes 64 biologics, accounting for 24%. Small molecules amount to 178 compounds, equating to 66%.”
Summary of the Report: Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. More pertinently, the degree and proportion of breakthrough innovations is significant. GBI Research analysis identified 59 first-in-class programs in the asthma pipeline, acting on 43 first-inclass molecular targets, accounting for 23% of all products with a disclosed molecular target and reflective of the high degree of innovation in this indication. This has far-reaching strategic implications for all market participants, as, despite the high clinical trial attrition rate, it is highly likely that many of the first-in-class technologies will reach the market over the coming decade and may transform the clinical and commercial landscape. This highlights both the commercial and clinical appeal of developing drugs of this class, and follows trends seen in other therapy areas, particularly oncology. Xolair (omalizumab), a recombinant humanized anti-IgE monoclonal Antibody (mAb), was the first humanized therapeutic mAb to be indicated for asthma. It was approved by the FDA in 2003 as an add-on therapy for adults and adolescents aged 12 and over, with moderate-to-severe allergic asthma and symptoms not adequately controlled with Inhaled Corticosteroids (ICS).
Click Here To Check Complete Report
Scope of the Report: The report analyzes innovation in asthma in the context of the overall pipeline and the current market landscape. In addition, it analyzes the deals landscape surrounding first-inclass products in asthma, and pinpoints opportunities for in-licensing. The report covers and includes • A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms • The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline • Comprehensive review of the pipeline for first-in-class therapies, analyzed by of stage of development, molecule type, and molecular target • Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets • Assessment of the licensing and co-development deal landscape for asthma therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products
Download Sample Brochure
Reasons to buy: The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to • Understand the focal shifts in molecular targets in the asthma pipeline • Understand the distribution of pipeline programs by phase of development, molecule type and molecular target • Access a scientific and clinical analysis of first-in-class developmental programs for asthma, benchmarked against non-first-in-class targets • Access a list of the first-in-class therapies potentially open to dealmaking opportunities
Make an Inquiry Before Buying
Frontier Pharma: Asthma- Identifying and Commercializing First- in- Class Innovation A detailed qualitative analysis of the factors responsible for driving and restraining growth of the Asthma Market are provided in the report.
Contact: 1-302-684-6088 sales@marketintelreports.com www.marketintelreports.com
Click here to order a copy of Asthma Market Report